Biosimilars Market Expected To Reach $48.52 Billion By 2030 As Growth Accelerates At 17.4% CAGR
Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Biosimilars Market Growth Analysis: How Will Revenue Expand During The Forecast Period?
The biosimilars sector has experienced swift expansion in recent years. Projections indicate an increase from $21.85 billion in 2025 to $25.53 billion in 2026, achieving a compound annual growth rate (CAGR) of 16.9%. Several factors have driven this historical growth, including the escalating incidence of chronic and autoimmune conditions, the substantial expense of reference biologics, a heightened need for affordable treatment options, progress in biopharmaceutical research and development, and the strengthening of healthcare systems within developing countries.
The biosimilars market is projected to experience significant growth over the coming years, with its value anticipated to reach $48.52 billion by 2030, expanding at a compound annual growth rate (CAGR) of 17.4%. This forecasted expansion is driven by the expiration of patents for major biologic drugs, heightened utilization of biosimilars in oncology and autoimmune treatments, favorable government policies and incentives, enhanced production capabilities in the Asia-Pacific region, and increased collaborations between biopharmaceutical firms and contract manufacturing organizations. Key trends shaping this period include the emergence of tailored biosimilar development, more cost-efficient biologic manufacturing, progress in regulatory alignment and compliance, growth of biosimilar markets in developing regions, and a rise in strategic alliances and joint ventures.
Download A Free Sample Report For Comprehensive Market Insights:
Biosimilars Market Development Factors: Which Trends Are Supporting Demand?
The rising costs of healthcare are anticipated to drive the expansion of the biosimilars market in the coming period. Healthcare expenditures encompass the overall amount spent on medical goods and services within a specific population or system. By providing more affordable options compared to costly biologic drugs, the biosimilar sector helps cut treatment expenses for patients and healthcare systems, thereby reducing overall healthcare spending. For example, in March 2024, the Health Foundation, an independent UK charity and think tank, reported that total health spending in England reached £182 billion ($196.78 billion) in 2022/23, the most recent year with confirmed data. Although planned health expenditures are expected to climb to £192 billion ($207.59 billion) in 2024/25, inflation will limit the real-term increase to just 0.6% relative to the 2023/24 fiscal year. Consequently, the growth of the biosimilars market is being fueled by increasing healthcare expenditures.
Biosimilars Market Segments: Where Are The Largest Growth Opportunities?
The biosimilars market covered in this report is segmented –
1) By Type: Monoclonal Antibodies, Insulin, Erythropoietin, Granulocyte-Colony Stimulating Factor, Other Hormones
2) By Protein Type: Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins
3) By Application: Oncology, Chronic And Autoimmune Diseases, Growth Hormone Deficiency, Infectious Diseases, Other Applications
Subsegments:
1) By Monoclonal Antibodies: IgG Biosimilars, Non-IgG Biosimilars
2) By Insulin: Rapid-Acting Insulin Biosimilars, Long-Acting Insulin Biosimilars, Premixed Insulin Biosimilars
3) By Erythropoietin: Epoetin Alfa Biosimilars, Darbepoetin Alfa Biosimilars
4) By Granulocyte-Colony Stimulating Factor (G-CSF): Filgrastim Biosimilars, Pegfilgrastim Biosimilars
5) By Other Hormones: Growth Hormones, Hormonal Replacement Therapy Biosimilars
Biosimilars Market Transformation Trends: Which Innovations Are Driving Change?
Key players in the biosimilars industry are concentrating on developing cutting-edge products to secure a competitive advantage within the sector. FYLNETRA, a leukocyte growth factor, is designed to reduce the occurrence of infections, particularly those presenting as febrile neutropenia, in patients with non-myeloid cancers who are undergoing myelosuppressive chemotherapy regimens linked to a notable risk of febrile neutropenia. A notable example occurred in May 2023, when Amneal Pharmaceuticals Inc., a pharmaceutical firm based in the United States, introduced FYLNETRA (pegfilgrastim-pbbk) to the market, a biosimilar referencing Neulasta, delivered in a prefilled single-dose syringe. This therapy addresses neutropenia—a condition characterized by low levels of neutrophils, the white blood cells essential for fighting infections—frequently experienced by individuals during chemotherapy.
Biosimilars Market Major Participants And Competitive Dynamics
Major companies operating in the biosimilars market are Amgen, Novartis AG, Samsung Bioepis Co. Ltd., Viatris, Celltrion Inc., Coherus Biosciences, Eli Lilly and Company, Dr. Reddy’s Laboratories, Roche India Pvt Ltd, Abbott India Limited, Wuxi Biologics, Shanghai Henlius Biotech, Innovent Biologics, Hisun Pharma, 3SBio, Beijing ShuangLu Pharmaceuticals, Qilu Pharmaceutical, Kyowa Hakko Kirin, Takeda, Mitsubishi Tanabe, AGC Biologics, Bio-Thera, Sandoz Pty Ltd, Apotex Pty Ltd, Cadila Pharmaceuticals, BiosanaPharma, GlaxoSmithKline, AstraZeneca, Bayer, Merck, Boehringer Ingelheim, Sanofi, Fresenius Kabi, Napp Pharmaceuticals, Mundipharma Deutschland GmbH & Co. KG, Geropharm, Valenta, NovaMedica, SynBio, Rani Therapeutics, Johnson & Johnson, Biogen Inc., Aché, Eurofarma, Teva Pharmaceuticals, Oramed Pharmaceuticals, Entera Bio, Julphar, Hikma Pharmaceuticals, BIOPHARMA-MEA, NeoTX, AID Genomics Limited, Altis Biologics, Cipla Medpro South Africa, Next Biosciences, Viome, Inqaba Biotechnical Industries (Pty)
Access The Complete Biosimilars Market Report:
Biosimilars Market Geographic Analysis: Where Is Demand Growing The Fastest?
North America was the largest region in the global biosimilars market in 2025. Middle East is expected to be the fastest-growing region in the forecast period. The regions covered in the biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
